TNAX-103A

N/A

Report date: 2023/10/09 14:42:33

Base Information

Drug NameTNAX-103A
Drug Alias NameTNAX-103ATNAX103A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-CMRF35-like molecule 8
TargetsCMRF35-like molecule 8
Therapy Area/IndicationsMyocardial InfarctionAcute Kidney InjurySpinal Cord Injuries +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Tsukuba
China Registration ClassN/A

Develop Information

Active CompaniesTNAX Biopharma Corp
Inactive CompaniesN/A
Active IndicationsMyocardial InfarctionAcute Kidney InjurySpinal Cord Injuries +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A